Biomarker-Guided Drug Development of YAP/TAZ-TEAD inhibitors

Time: 12:15 pm
day: Conference Day One


  • SW-682: preclinical data for a novel TEAD inhibitor for Hippo-mutant cancers
  • Overview of potential biomarkers for patient stratification, target engagement and molecular response
  • Biomarkers for YAP activation as oncogenic driver or resistance mechanism to targeted therapies